Latest Conference Articles

November 9th 2016, 5:07am

SMR Congress

The combination of dabrafenib and trametinib continued to demonstrate durable efficacy for patients with BRAF V600E/K-mutant melanoma across patient subgroups in a 3-year analysis of the phase III COMBI-d study, with baseline site of metastasis identified as a predictor of overall survival ≥36 months,

November 9th 2016, 1:47am

SMR Congress

Graham Mann, MBBS, PhD, FRACP, professor of Medicine, Westmead Clinical School and co-director of the Centre for Cancer Research, The Westmead Institute for Medical Research at the University of Sydney in Australia, discusses his findings from the Australian Melanoma Genome Project, which were presented at the 2016 Society for Melanoma Research (SMR) Congress.

November 9th 2016, 1:14am

SMR Congress

Stefani Spranger, PhD, postdoctoral fellow at the University of Chicago, discusses recent findings about why a certain subgroup of patients with melanoma do not have T cells within their tumor microenvironment.

November 8th 2016, 11:38pm

SMR Congress

Helmut Schiader, MD, discusses why drug resistance may be due to epigenetic changes and not mutation-induced changes, as well as the role of immunotherapy/targeted therapy combinations in combating resistance.

November 8th 2016, 5:39am

SMR Congress

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

November 8th 2016, 5:00am

SMR Congress

Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses some of the early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma.

November 8th 2016, 4:12am

SMR Congress

Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.

November 8th 2016, 3:33am

LUGPA Annual Meeting

Clinical research in private practice is thriving and the future is bright.

November 8th 2016, 2:46am

SMR Congress

Ryan Sullivan, MD, Massachusetts General Hospital, discusses how best to treat patients with melanoma who have the BRAF mutation.

November 8th 2016, 1:12am

LUGPA Annual Meeting

The Large Urology Group Practice Association has announced the plan to create two alternative payment models that involve bundled payments.

November 8th 2016, 12:54am

LUGPA Annual Meeting

David Albala, MD, discusses some of the benefits of robotic surgery and the impact it has had on the field of prostate cancer, as well as methods that larger urology groups can use to better achieve compliance.

November 7th 2016, 11:11pm

SMR Congress

The addition of the PD-L1 inhibitor atezolizumab to the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib induced a high response rate for patients with BRAF-mutant unresectable melanoma.

November 7th 2016, 9:40pm

LUGPA Annual Meeting

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.

November 7th 2016, 8:58pm

LUGPA Annual Meeting

Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discussed the use of fusion MRI in prostate cancer with OncLive during the LUGPA Annual Meeting.

November 7th 2016, 3:40am

LUGPA Annual Meeting

With immunotherapy agents showing significant promise in bladder cancer, the potential for these agents in the neoadjuvant setting is wide open.

November 7th 2016, 12:24am

LUGPA Annual Meeting

Whatever the result of the US presidential election, the era ahead will continue to be one of unprecedented change in healthcare, according to Robert Laszewski.

November 6th 2016, 10:37pm

LUGPA Annual Meeting

November 6th 2016, 9:30pm

LUGPA Annual Meeting

Following a long drought in the development of bladder cancer treatments, the field is now poised to benefit from a series of rapid advances ushered in by highly effective immunotherapies.

November 6th 2016, 12:33am

Kidney Cancer Symposium

The dual inhibitor combination of lenvatinib and everolimus is becoming an essential second-line treatment option in advanced renal cell carcinoma, and research to move the regimen into frontline settings is underway.

November 5th 2016, 11:45pm

LUGPA Annual Meeting

A window of opportunity exists in which some patients with non–muscle-invasive bladder cancer could benefit from trying novel second-line therapies prior to surgery.